Menu

About OIC

OIC and pain control OIC negatively impacts QOL The role of mu-opioid receptors Laxative failure: what’s next?

About MOVENTIG (naloxegol)

Mechanism of action SBM efficacy Safety Prescribing information

OIC Checklist

OIC treatment checklist

MOA, mechanism of action; OIC, opioid-induced constipation; QOL, quality of life; SBM, spontaneous bowel movement.

Moventig Story

When they only share some of their story…

…they can only get part of your help

For the United Kingdom:

Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

UK Prescribing Information can be found here.

Could uncovering what patients are holding back lead to better care?

Discover the whole story arrow icon

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

KKI/INT/MOV/0107 February 2025

This material is not optimised for mobile operating systems. Please log-in using a desktop device.

This material is not optimised for mobile operating systems. Please log-in using a desktop device.